The University of Chicago Header Logo

Ryan Widau

TitlePostdoctoral Scholar
InstitutionUniversity of Chicago
DepartmentRadiation Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Finn RS, Yau T, Hsu CH, De Toni EN, Goyal L, Galle PR, Qin S, Rao S, Sun F, Wang C, Widau RC, Zhu AX. Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha Fetoprotein Following Non-Sorafenib Systemic Therapy: An Expansion Cohort of REACH-2. Oncologist. 2022 12 09; 27(12):e938-e948. PMID: 36190331; PMCID: PMC10249425.
      Citations: 8     Fields:    Translation:Humans
    2. Zhu AX, Lin Y, Ferry D, Widau RC, Saha A. Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors. Immunotherapy. 2022 Nov; 14(16):1341-1351. PMID: 36285590.
      Citations: 5     Fields:    Translation:Humans
    3. Shao G, Bai Y, Yuan X, Chen X, Gu S, Gu K, Hu C, Liang H, Guo Y, Wang J, Yen CJ, Lee VH, Wang C, Widau RC, Zhang W, Liu J, Zhang Q, Qin S. Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study. EClinicalMedicine. 2022 Dec; 54:101679. PMID: 36247923; PMCID: PMC9562926.
      Citations: 1     
    4. Llovet JM, Singal AG, Villanueva A, Finn RS, Kudo M, Galle PR, Ikeda M, Callies S, McGrath LM, Wang C, Abada P, Widau RC, Gonzalez-Gugel E, Zhu AX. Prognostic and Predictive Factors in Patients with Advanced HCC and Elevated Alpha-Fetoprotein Treated with Ramucirumab in Two Randomized Phase III Trials. Clin Cancer Res. 2022 06 01; 28(11):2297-2305. PMID: 35247922; PMCID: PMC9662930.
      Citations: 4     Fields:    Translation:Humans
    5. Galle PR, Kudo M, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX, Touchefeu Y. Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease aetiology. Liver Int. 2021 11; 41(11):2759-2767. PMID: 34173317.
      Citations: 3     Fields:    Translation:Humans
    6. Kudo M, Finn RS, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet JM, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX. Ramucirumab for Patients with Intermediate-Stage Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Results from Two Phase 3 Studies (REACH and REACH-2). Liver Cancer. 2021 Sep; 10(5):451-460. PMID: 34721507; PMCID: PMC8527922.
      Citations: 5     
    7. Kudo M, Ikeda M, Yamashita T, Finn RS, Liang K, Wang C, Sakaguchi S, Abada P, Widau RC, Zhu AX, Galle PR. Ramucirumab in patients with advanced hepatocellular carcinoma and elevated a-fetoprotein: Outcomes by treatment-emergent ascites. Hepatol Res. 2021 Jun; 51(6):715-721. PMID: 33743189.
      Citations: 3     
    8. Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, Kudo M, Gerken G. Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. Br J Cancer. 2021 04; 124(8):1388-1397. PMID: 33531690; PMCID: PMC8039038.
      Citations: 22     Fields:    Translation:HumansCellsCTClinical Trials
    9. Galle PR, Kudo M, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX, Reig M. Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. Liver Int. 2021 03; 41(3):598-607. PMID: 33188713; PMCID: PMC7898500.
      Citations: 9     Fields:    Translation:Humans
    10. Kudo M, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Chan SL, Palmer DH, Ikeda M, Yamashita T, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX, Assenat E, Merle P, Vogel A. Effect of ramucirumab on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. JHEP Rep. 2021 Apr; 3(2):100215. PMID: 33392490; PMCID: PMC7772786.
      Citations: 18     
    11. Kudo M, Galle PR, Llovet JM, Finn RS, Vogel A, Motomura K, Assenat E, Merle P, Brandi G, Daniele B, Okusaka T, Dadduzio V, Morimoto M, Jen MH, Drove Ubreva N, Widau RC, Shinozaki K, Yoshikawa R, Zhu AX, Tomášek J, Borg C, Pracht M. Ramucirumab in elderly patients with hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib in REACH and REACH-2. Liver Int. 2020 08; 40(8):2008-2020. PMID: 32279446.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    12. Meyer T, Finn R, Kudo M, Kang Y, Yen C, Galle P, Llovet J, Assenat E, Brandi G, Motomura K, Okusaka T, Hubner R, Karwal M, Baron A, Ikeda M, Liang K, Wang C, Widau R, Schelman W, Zhu A. Ramucirumab in advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: outcomes by prior transarterial chemoembolisation from two randomised, double-blind, placebo-controlled phase 3 studies (REACH-2 and REACH). Ann Oncol. 2019 Jul; 30 Suppl 4:iv133. PMID: 32085038.
    13. Herbst RS, Arkenau HT, Santana-Davila R, Paz-Ares L, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, Chau I, Calvo E, Cassier PA, Isambert N. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial. Lancet Oncol. 2019 08; 20(8):1109-1123. PMID: 31301962.
      Citations: 108     Fields:    Translation:HumansCTClinical Trials
    14. Ranoa DRE, Widau RC, Mallon S, Parekh AD, Nicolae CM, Huang X, Bolt MJ, Arina A, Parry R, Kron SJ, Moldovan GL, Khodarev NN, Weichselbaum RR. STING Promotes Homeostasis via Regulation of Cell Proliferation and Chromosomal Stability. Cancer Res. 2019 04 01; 79(7):1465-1479. PMID: 30482772; PMCID: PMC6445702.
      Citations: 42     Fields:    Translation:HumansAnimals
    15. Arkenau HT, Martin-Liberal J, Penel N, Krebs MG, Herbst RS, Walgren RA, Widau RC, Mi G, Jin J, Ferry D, Chau I, Calvo E. Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF). Oncologist. 2018 12; 23(12):1407-e136. PMID: 29853658; PMCID: PMC6292555.
      Citations: 65     Fields:    Translation:HumansCTClinical Trials
    16. Reck M, Garon EB, Paz-Ares L, Ponce S, Juan O, Kiura K, Widau RC, He S, Dalal R, Lee P, Nakagawa K, Jaime JC, Nadal E. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results. Clin Lung Cancer. 2018 05; 19(3):213-220.e4. PMID: 29317191.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    17. Petrylak DP, de Wit R, Chi KN, Drakaki A, Sternberg CN, Nishiyama H, Castellano D, Hussain S, Bamias A, Yu EY, van der Heijden MS, Matsubara N, Alekseev B, Necchi A, Ou YC, Coskun HS, Su WP, Percent IJ, Lee JL, Tucci M, Semenov A, Laestadius F, Peer A, Tortora G, Safina S, Rodriguez-Vida A, Cicin I, Harputluoglu H, Widau RC, Liepa AM, Walgren RA, Hamid O, Zimmermann AH, Bell-McGuinn KM, Powles T, RANGE study investigators, Fléchon A, Géczi L, Hegemann M, Del Muro XG. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet. 2017 Nov 18; 390(10109):2266-2277. PMID: 28916371.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    18. Widau RC, Parekh AD, Ranck MC, Golden DW, Kumar KA, Sood RF, Pitroda SP, Liao Z, Huang X, Darga TE, Xu D, Huang L, Andrade J, Roizman B, Weichselbaum RR, Khodarev NN. RIG-I-like receptor LGP2 protects tumor cells from ionizing radiation. Proc Natl Acad Sci U S A. 2014 Jan 28; 111(4):E484-91. PMID: 24434553; PMCID: PMC3910628.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    19. Spiotto MT, Pytynia M, Liu GF, Ranck MC, Widau R. Animal models to study the mutational landscape for oral cavity and oropharyngeal cancers. J Oral Maxillofac Res. 2013 Apr 01; 4(1):e1. PMID: 24422024; PMCID: PMC3886108.
      Citations: 4     
    20. Widau RC, Zheng Y, Sung CY, Zelivianskaia A, Roach LE, Bachmeyer KM, Abramova T, Desgardin A, Rosner A, Cunningham JM, Skapek SX. p19Arf represses platelet-derived growth factor receptor ß by transcriptional and posttranscriptional mechanisms. Mol Cell Biol. 2012 Nov; 32(21):4270-82. PMID: 22907756; PMCID: PMC3486135.
      Citations: 13     Fields:    Translation:AnimalsCells
    21. Zhang L, Widau RC, Herring BP, Gallagher PJ. Delta-like 1-Lysine613 regulates notch signaling. Biochim Biophys Acta. 2011 Dec; 1813(12):2036-43. PMID: 21985982; PMCID: PMC3217118.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    22. Widau RC, Jin Y, Dixon SA, Wadzinski BE, Gallagher PJ. Protein phosphatase 2A (PP2A) holoenzymes regulate death-associated protein kinase (DAPK) in ceramide-induced anoikis. J Biol Chem. 2010 Apr 30; 285(18):13827-38. PMID: 20220139; PMCID: PMC2859546.
      Citations: 22     Fields:    Translation:HumansCells
    Widau's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (118)
    Co-Authors (10)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors